Jill S Halterman1, Maria Fagnano1, Reynaldo S Tajon1, Paul Tremblay1, Hongyue Wang2, Arlene Butz3, Tamara T Perry4, Kenneth M McConnochie1. 1. Department of Pediatrics, University of Rochester, Rochester, New York. 2. Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York. 3. Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland. 4. Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock.
Abstract
Importance: Poor adherence to recommended preventive asthma medications is common, leading to preventable morbidity. We developed the School-Based Telemedicine Enhanced Asthma Management (SB-TEAM) program to build on school-based supervised therapy programs by incorporating telemedicine at school to overcome barriers to preventive asthma care. Objective: To evaluate the effect of the SB-TEAM program on asthma morbidity among urban children with persistent asthma. Design, Setting, and Participants: In this randomized clinical trial, children with persistent asthma aged 3 to 10 years in the Rochester City School District in Rochester, New York, were stratified by preventive medication use at baseline and randomly assigned to theSB-TEAM program or enhanced usual care for 1 school year. Participants were enrolled at the beginning of the school year (2012-2016), and outcomes were assessed through the end of the school year. Data were analyzed between May 2017 and November 2017 using multivariable modified intention-to-treat analyses. Interventions: Supervised administration of preventive asthma medication at school as well as 3 school-based telemedicine visits to ensure appropriate assessment, preventive medication prescription, and follow-up care. The school site component of the telemedicine visit was completed by telemedicine assistants, who obtained history and examination data. These data were stored in a secure virtual waiting room and then viewed by the primary care clinician, who completed the assessment and communicated with caregivers via videoconference or telephone. Preventive medication prescriptions were sent to pharmacies that deliver to schools for supervised daily administration. Main Outcomes and Measures: The primary outcome was the mean number of symptom-free days per 2 weeks, assessed by bimonthly blinded interviews. Results: Of the 400 enrolled children, 247 (61.8%) were male and 230 (57.5%) were African American, and the mean (SD) age was 7.8 (1.7) years. Demographic characteristics and asthma severity in the 2 groups were similar at baseline. Among children in the SB-TEAM group, 196 (98.0%) had 1 or more telemedicine visits, and 165 (82.5%) received supervised therapy through school. We found that children in the SB-TEAM group had more symptom-free days per 2 weeks postintervention compared with children in the enhanced usual care group (11.6 vs 10.97; difference, 0.69; 95% CI, 0.15-1.22; P = .01), with the largest difference observed at the final follow-up (difference, 0.85; 95% CI, 0.10-1.59). In addition, children in the SB-TEAM group were less likely to have an emergency department visit or hospitalization for asthma (7% vs 15%; odds ratio, 0.52; 95% CI, 0.32-0.84). Conclusions and Relevance: The SB-TEAM intervention significantly improved symptoms and reduced health care utilization among urban children with persistent asthma. This program could serve as a model for sustainable asthma care among school-aged children. Trial Registration: clinicaltrials.gov Identifier: NCT01650844.
RCT Entities:
Importance: Poor adherence to recommended preventive asthma medications is common, leading to preventable morbidity. We developed the School-Based Telemedicine Enhanced Asthma Management (SB-TEAM) program to build on school-based supervised therapy programs by incorporating telemedicine at school to overcome barriers to preventive asthma care. Objective: To evaluate the effect of the SB-TEAM program on asthma morbidity among urban children with persistent asthma. Design, Setting, and Participants: In this randomized clinical trial, children with persistent asthma aged 3 to 10 years in the Rochester City School District in Rochester, New York, were stratified by preventive medication use at baseline and randomly assigned to the SB-TEAM program or enhanced usual care for 1 school year. Participants were enrolled at the beginning of the school year (2012-2016), and outcomes were assessed through the end of the school year. Data were analyzed between May 2017 and November 2017 using multivariable modified intention-to-treat analyses. Interventions: Supervised administration of preventive asthma medication at school as well as 3 school-based telemedicine visits to ensure appropriate assessment, preventive medication prescription, and follow-up care. The school site component of the telemedicine visit was completed by telemedicine assistants, who obtained history and examination data. These data were stored in a secure virtual waiting room and then viewed by the primary care clinician, who completed the assessment and communicated with caregivers via videoconference or telephone. Preventive medication prescriptions were sent to pharmacies that deliver to schools for supervised daily administration. Main Outcomes and Measures: The primary outcome was the mean number of symptom-free days per 2 weeks, assessed by bimonthly blinded interviews. Results: Of the 400 enrolled children, 247 (61.8%) were male and 230 (57.5%) were African American, and the mean (SD) age was 7.8 (1.7) years. Demographic characteristics and asthma severity in the 2 groups were similar at baseline. Among children in the SB-TEAM group, 196 (98.0%) had 1 or more telemedicine visits, and 165 (82.5%) received supervised therapy through school. We found that children in the SB-TEAM group had more symptom-free days per 2 weeks postintervention compared with children in the enhanced usual care group (11.6 vs 10.97; difference, 0.69; 95% CI, 0.15-1.22; P = .01), with the largest difference observed at the final follow-up (difference, 0.85; 95% CI, 0.10-1.59). In addition, children in the SB-TEAM group were less likely to have an emergency department visit or hospitalization for asthma (7% vs 15%; odds ratio, 0.52; 95% CI, 0.32-0.84). Conclusions and Relevance: The SB-TEAM intervention significantly improved symptoms and reduced health care utilization among urban children with persistent asthma. This program could serve as a model for sustainable asthma care among school-aged children. Trial Registration: clinicaltrials.gov Identifier: NCT01650844.
Authors: G E Matt; D R Wahlgren; M F Hovell; J M Zakarian; J T Bernert; S B Meltzer; J L Pirkle; S Caudill Journal: Tob Control Date: 1999 Impact factor: 7.552
Authors: C F LaForce; D S Pearlman; M E Ruff; W S Silvers; S W Weinstein; D S Clements; A Brown; S Duke; S M Harding; K W House Journal: Ann Allergy Asthma Immunol Date: 2000-11 Impact factor: 6.347
Authors: Lynn B Gerald; Leslie A McClure; Joan M Mangan; Kathy F Harrington; Linda Gibson; Sue Erwin; Jody Atchison; Roni Grad Journal: Pediatrics Date: 2009-02 Impact factor: 7.124
Authors: David E Capo-Ramos; Catherine Duran; Alan E Simon; Lara J Akinbami; Kenneth C Schoendorf Journal: J Asthma Date: 2014-03-20 Impact factor: 2.515
Authors: Laurie J Bauman; Elizabeth Wright; Frederick E Leickly; Ellen Crain; Deanna Kruszon-Moran; Shari L Wade; Cynthia M Visness Journal: Pediatrics Date: 2002-07 Impact factor: 7.124
Authors: Kenneth M McConnochie; Jonathan Tan; Nancy E Wood; Neil E Herendeen; Harriet J Kitzman; Jason Roy; Klaus J Roghmann Journal: Telemed J E Health Date: 2007-08 Impact factor: 3.536
Authors: Tyra Bryant-Stephens; C Kenyon; A J Apter; Courtney Wolk; Yolanda S Williams; R Localio; K Toussaint; A Hui; C West; Yvonne Stewart; S McGinnis; M Gutierrez; R Beidas Journal: J Asthma Date: 2019-06-26 Impact factor: 2.515
Authors: Christina Crabtree-Ide; Denise F Lillvis; Jing Nie; Maria Fagnano; Reynaldo S Tajon; Paul Tremblay; Jill S Halterman; Katia Noyes Journal: Popul Health Manag Date: 2021-05-14 Impact factor: 2.459
Authors: Jill S Halterman; Kristin A Riekert; Maria Fagnano; Paul J Tremblay; Susan W Blaakman; Reynaldo Tajon; Hongyue Wang; Belinda Borrelli Journal: J Asthma Date: 2021-01-08 Impact factor: 2.515
Authors: Lucy C Holmes; Heather Orom; Heather K Lehman; Stacie Lampkin; Jill S Halterman; Vanessa Akiki; Alicia A Supernault-Sarker; Susan B Butler; Denise Piechowski; Patricia M Sorrentino; Ziqiang Chen; Gregory E Wilding Journal: J Asthma Date: 2021-01-06 Impact factor: 2.515